

# ADSTILADRIN<sup>®</sup> and Medicare

**ADSTILADRIN<sup>®</sup>**  
(nadofaragene firadenovec-vncg)  
suspension, for intravesical use / 3 x 10<sup>11</sup> viral particles/mL

## Understanding Part-B coverage and reimbursement

- **Medicare Part-B covers** drugs administered by infusion or injection in physician offices and hospital outpatient departments<sup>1</sup>
- **Drugs covered under Part-B** must be reasonable and necessary for the diagnosis or treatment of an illness or injury<sup>1</sup>
- **Coverage can depend on multiple factors**, including patient diagnosis, type of drug, route of administration, and administration setting<sup>1</sup>
- Per Centers for Medicare and Medicaid Services (CMS), **the allowable amount for reimbursement of products under Part-B is ASP + 6%**<sup>1,2</sup>

**References:** **1.** Medicare Payment Advisory Commission (MedPAC). Part B drugs payment systems. Accessed March 25, 2024. [https://www.medpac.gov/wp-content/uploads/2021/11/MedPAC\\_Payment\\_Basics\\_22\\_PartB\\_FINAL\\_SEC.pdf](https://www.medpac.gov/wp-content/uploads/2021/11/MedPAC_Payment_Basics_22_PartB_FINAL_SEC.pdf) **2.** Centers for Medicare & Medicaid Services. Medicare Part B Drug Average Sales Price. Accessed March 25, 2024. <https://www.cms.gov/medicare/payment/part-b-drugs>

© 2024 Ferring. ADSTILADRIN, Ferring and the Ferring Pharmaceuticals logo are trademarks of Ferring. US-ADST-2300214 v2 04/24



Scan the QR code to learn more about Part-B reimbursement

Scan the QR code to review the CMS ASP Pricing File



**FERRING**  
PHARMACEUTICALS



**ADSTILADRIN<sup>®</sup>**

(nadofaragene firadenovec-vncg)

suspension, for intravesical use /  $3 \times 10^{11}$  viral particles/mL